Abionyx Pharma, Racers study testifies results of Cer-001 against sepsis

The Racers study was presented in the suggestive setting of Palazzo Francesco Turati in Milan. , the first biological drug capable of modulating inflammation in sepsis, a disease with a very high mortality rate.